Vitamin D Status and Multi-Omics Profiles in Primary Osteoporosis (NCT07296471) | Clinical Trial Compass
RecruitingNot Applicable
Vitamin D Status and Multi-Omics Profiles in Primary Osteoporosis
China120 participantsStarted 2025-11-11
Plain-language summary
This observational study aims to explore the relationships between vitamin D status and genomic, proteomic, and metabolomic profiles in patients with primary osteoporosis.
Eligible participants are adults who are newly diagnosed with primary osteoporosis at Yichang Second People's Hospital. Blood samples will be collected at the initial diagnosis to analyze gene expression, protein levels, and metabolic profiles.
Participants will receive standard clinical treatment according to routine care, but no additional research sampling or follow-up will be performed.
The study seeks to identify molecular patterns associated with osteoporosis and improve understanding of patient responses to therapy.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Healthy controls: Adults aged ≥18 years, with normal bone mineral density (BMD) confirmed by dual-energy X-ray absorptiometry (DXA), without a history of bone metabolic diseases, major organ dysfunction, or chronic inflammatory/autoimmune diseases.
✓. Osteoporotic patients: Adults aged ≥18 years, newly diagnosed with primary osteoporosis according to clinical criteria (T-score ≤ -2.5 SD by DXA), without serious complications that may affect study results.
✓. Participants willing and able to provide written informed consent and cooperate with study procedures, including blood and serum sample collection and clinical data recording.
Exclusion criteria
✕. Patients with secondary osteoporosis, including but not limited to osteoporosis caused by hyperparathyroidism, tumors, chronic kidney disease, liver cirrhosis, rheumatoid arthritis, or other autoimmune diseases.
✕. Individuals who have taken vitamin D supplements, anti-osteoporotic drugs, glucocorticoids, or other medications affecting vitamin D or bone metabolism within 3 months prior to enrollment.
✕. Pregnant or lactating women, or individuals with mental disorders preventing cooperation with study procedures.
What they're measuring
1
Gene Expression Profiles Derived From Transcriptomic Analysis
Timeframe: Baseline
2
Serum Protein Abundance Profiles From Proteomic Analysis
Timeframe: Baseline
3
Serum Metabolite Abundance Profiles From Metabolomics Analysis
. Individuals with acute infections, malignant tumors, or severe liver, kidney, cardiovascular, or cerebrovascular diseases that may affect study outcomes.
✕. Participants with a history of blood transfusion within 1 month prior to enrollment or those unable to provide peripheral blood samples as required.